AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38371194 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 159
Study 38371290 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg inclisiran sodium on days 1, 90, and 270
Number of subjects: 345
Study 38371290 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 345
Study 38371314 — intervention group
Group type: EXPERIMENTAL
Intervention: octocog alfa (prophylaxis)
Number of subjects: 711
Study 38371314 — intervention group
Group type: COMPARATOR
Intervention: octocog alfa (on-demand therapy)
Number of subjects: 711
Study 38371479 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg subcutaneously once weekly for 12 weeks
Number of subjects: 255
Study 38371479 — intervention group
Group type: COMPARATOR
Intervention: Placebo subcutaneously once weekly for 12 weeks
Number of subjects: 255
Study 38371479 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 255
Study 38371479 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study 38371485 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP-guided management
Number of subjects: 81
Study 38371485 — intervention group
Group type: COMPARATOR
Intervention: Standard care (guided by clinical findings only)
Number of subjects: 81
Study 38372128 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylometazoline hydrochloride 0.1% (Otrivin)
Number of subjects: 136
Study 38372148 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical repair of proximal hamstring ruptures
Number of subjects: 12
Study 38372592 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition-Focused Physical Exam (NFPE) conducted by registered dietitian nutritionists (RDNs)
Number of subjects: 541
Study 38372621 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-dose dolutegravir (50 mg twice daily)
Number of subjects: 35
Study 38372621 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose dolutegravir
Number of subjects: 35
Study 38372621 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-dose dolutegravir
Number of subjects: 35
Study 38372622 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone (70 mg bolus followed by 400-840 mg/24 h)
Number of subjects: 170
Study 38372622 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 170
Study 38372622 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone (300 mg bolus followed by 600-1800 mg/24 h)
Number of subjects: 170
Study 38372727 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadonilimab 15 mg/kg every 3 weeks plus chemotherapy
Number of subjects: 45
Study 38372727 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadonilimab 10 mg/kg every 3 weeks plus chemotherapy
Number of subjects: 45
Study 38372727 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadonilimab 10 mg/kg every 3 weeks plus chemotherapy and bevacizumab
Number of subjects: 45
Study 38372727 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadonilimab 10 mg/kg every 3 weeks plus chemotherapy and bevacizumab (combined with cohort A-10)
Number of subjects: 45
Study 38372727 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadonilimab (all cohorts)
Number of subjects: 45
Study 38372727 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadonilimab combined with standard therapy
Number of subjects: 45
Study 38372798 — intervention group
Group type: EXPERIMENTAL
Intervention: Red palm olein (RPOO)
Number of subjects: 156
Study 38372798 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra virgin coconut oil (EVCO)
Number of subjects: 156
Study 38372798 — intervention group
Group type: COMPARATOR
Intervention: Extra virgin olive oil (EVOO)
Number of subjects: 156
Study 38372904 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (oral daily for 52 weeks)
Number of subjects: 12
Study 38372938 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2982772 (960 mg once-daily modified-release formulation)
Number of subjects: 29
Study 38372938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 38372949 — intervention group
Group type: EXPERIMENTAL
Intervention: PY314 10 mg/kg in combination with pembrolizumab 200 mg IV every 21 days
Number of subjects: 17
Study 38372981 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual edaravone dexborneol (edaravone, 30 mg; dexborneol, 6 mg)
Number of subjects: 914
Study 38372981 — intervention group
Group type: COMPARATOR
Intervention: Placebo (edaravone, 0 mg; dexborneol, 60 μg)
Number of subjects: 914
Study 38372981 — intervention group
Group type: COMPARATOR
Intervention: Both groups (edaravone dexborneol and placebo)
Number of subjects: 914
Study 38372998 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based maternal and newborn care services package
Number of subjects: 7598
Study 38372998 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 7598
Study 38373025 — intervention group
Group type: EXPERIMENTAL
Intervention: S4E mHealth intervention
Number of subjects: 100
Study 38373025 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study 38373029 — intervention group
Group type: EXPERIMENTAL
Intervention: iSMART intervention
Number of subjects: 24
Study 38373029 — intervention group
Group type: COMPARATOR
Intervention: Manual of stroke rehabilitation (attention control)
Number of subjects: 24
Study 38373037 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-MICART+EMAs for 6 weeks
Number of subjects: 50
Study 38373037 — intervention group
Group type: COMPARATOR
Intervention: EMAs only for 6 weeks
Number of subjects: 50
Study 38373429 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental stroking before heel lance (intervention group)
Number of subjects: 112
Study 38373429 — intervention group
Group type: COMPARATOR
Intervention: Parental stroking after heel lance (control group)
Number of subjects: 112
Study 38373534 — intervention group
Group type: EXPERIMENTAL
Intervention: soul food vegan diet (n = 77)
Number of subjects: 159
Study 38373534 — intervention group
Group type: COMPARATOR
Intervention: soul food omnivorous diet (n = 82)
Number of subjects: 159
Study 38373596 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation in COPD patients receiving EBV
Number of subjects: 97
Study 38373596 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher number of TTs
Number of subjects: 97
Study 38373673 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic Mechanical Ventilation (MV)
Number of subjects: 60
Study 38373673 — intervention group
Group type: COMPARATOR
Intervention: Manual Bag Ventilation (BV)
Number of subjects: 60
Study 38373694 — intervention group
Group type: EXPERIMENTAL
Intervention: Yeast fermented (YF) bread made of bread wheat
Number of subjects: 40
Study 38373694 — intervention group
Group type: EXPERIMENTAL
Intervention: Yeast fermented (YF) bread made of spelt
Number of subjects: 40
Study 38373694 — intervention group
Group type: EXPERIMENTAL
Intervention: Yeast fermented (YF) bread made of emmer
Number of subjects: 40
Study 38373694 — intervention group
Group type: EXPERIMENTAL
Intervention: Sourdough fermented (SF) bread made of bread wheat
Number of subjects: 40
Study 38373694 — intervention group
Group type: EXPERIMENTAL
Intervention: Sourdough fermented (SF) bread made of spelt
Number of subjects: 40
Study 38373694 — intervention group
Group type: EXPERIMENTAL
Intervention: Sourdough fermented (SF) bread made of emmer
Number of subjects: 40
Study 38373694 — intervention group
Group type: EXPERIMENTAL
Intervention: Yeast fermented (YF) breads overall
Number of subjects: 40
Study 38373694 — intervention group
Group type: EXPERIMENTAL
Intervention: Sourdough fermented (SF) breads overall
Number of subjects: 40
Study 38373818 — intervention group
Group type: EXPERIMENTAL
Intervention: Plantar compartment block
Number of subjects: 30
Study 38373857 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Detection and Treatment to Reduce Events with Agitation Tool (ED-TREAT)
Number of subjects: 26
Study 38373857 — intervention group
Group type: EXPERIMENTAL
Intervention: ED-TREAT
Number of subjects: 26
Study 38373864 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of cardiac rhythm monitoring devices, echocardiography, biomarkers, and neuroimaging.
Number of subjects: 0
Study 38373918 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric Appendicitis Score (PAS) for PG group
Number of subjects: 124
Study 38373918 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric Appendicitis Score (PAS) for FG group
Number of subjects: 124
Study 38373918 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) levels
Number of subjects: 124
Study 38373918 — intervention group
Group type: COMPARATOR
Intervention: Pediatric Appendicitis Score (PAS) < 4
Number of subjects: 124
Study 38373918 — intervention group
Group type: COMPARATOR
Intervention: Comparison of PAS scores between PG and FG
Number of subjects: 124
Study 38373922 — intervention group
Group type: EXPERIMENTAL
Intervention: Very high positive, low negative trajectory
Number of subjects: 215
Study 38373922 — intervention group
Group type: EXPERIMENTAL
Intervention: High positive, moderate negative trajectory
Number of subjects: 215
Study 38373922 — intervention group
Group type: EXPERIMENTAL
Intervention: Very high positive, moderate negative trajectory
Number of subjects: 215
Study 38373922 — intervention group
Group type: EXPERIMENTAL
Intervention: High positive, high negative trajectory
Number of subjects: 215
Study 38373934 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic training for 4 weeks
Number of subjects: 43
Study 38373934 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic training for 4 weeks
Number of subjects: 43
Study 38373934 — intervention group
Group type: COMPARATOR
Intervention: Home isometric exercise (control group) for 4 weeks
Number of subjects: 43
Study 38373937 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led individualized review of pharmacotherapeutic plans
Number of subjects: 432
Study 38373937 — intervention group
Group type: COMPARATOR
Intervention: Usual management practice
Number of subjects: 432
Study 38373948 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive fantasizing
Number of subjects: 100
Study 38373948 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based interventions
Number of subjects: 100
Study 38373948 — intervention group
Group type: COMPARATOR
Intervention: Positive fantasizing and mindfulness
Number of subjects: 100
Study 38374026 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-transplantation cyclophosphamide (PTCy) 50 mg/kg/d at days +3 and +4 plus standard GVHD prophylaxis
Number of subjects: 89
Study 38374026 — intervention group
Group type: COMPARATOR
Intervention: Anti-thymocyte globulin (ATG) 5 mg/kg plus standard GVHD prophylaxis
Number of subjects: 89
Study 38374026 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-transplantation cyclophosphamide (PTCy)
Number of subjects: 89
Study 38374026 — intervention group
Group type: COMPARATOR
Intervention: Anti-thymocyte globulin (ATG)
Number of subjects: 89
Study 38374062 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronomic trabectedin combined with low-dose cyclophosphamide
Number of subjects: 50
Study 38374084 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen-Free Time with Friends intervention
Number of subjects: 75
Study 38374091 — intervention group
Group type: EXPERIMENTAL
Intervention: adjuvant trastuzumab
Number of subjects: 909
Study 38374091 — intervention group
Group type: EXPERIMENTAL
Intervention: RNA-seq data as a surrogate
Number of subjects: 909
Study 38374100 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance Care Planning (ACP) intervention with implementation support for 18 months.
Number of subjects: 420
Study 38374100 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving the same implementation support after the intervention period.
Number of subjects: 420
Study 38374100 — intervention group
Group type: EXPERIMENTAL
Intervention: Triadic sub-study involving patients, next of kin, and attending clinicians.
Number of subjects: 420
Study 38374100 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical data and health register data collected from patients.
Number of subjects: 420
Study 38374100 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire for clinical staff in both arms before and during the implementation period.
Number of subjects: 420
Study 38374100 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews in intervention units with various stakeholders.
Number of subjects: 420
Study 38374100 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis evaluating resource utilization and costs.
Number of subjects: 420
Study 38374103 — intervention group
Group type: EXPERIMENTAL
Intervention: ECMO-AI (ECMO-associated infections)
Number of subjects: 602
Study 38374103 — intervention group
Group type: EXPERIMENTAL
Intervention: ECMO-AI
Number of subjects: 602
Study 38374126 — intervention group
Group type: EXPERIMENTAL
Intervention: FACE self-help app (active intervention group)
Number of subjects: 250
Study 38374126 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 250
Study 38374149 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFAs (O-3 + TRAIN group)
Number of subjects: 26
Study 38374149 — intervention group
Group type: COMPARATOR
Intervention: Medium chain triglycerides (MCTs; TRAIN group)
Number of subjects: 26
Study 38374149 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFAs (O-3 + SEDEN group)
Number of subjects: 26
Study 38374158 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking outdoors
Number of subjects: 164
Study 38374158 — intervention group
Group type: COMPARATOR
Intervention: Walking indoors
Number of subjects: 164
Study 38374347 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 480 mg every 4 weeks and regorafenib 80 mg daily (3-weeks-on/1-week-off schedule)
Number of subjects: 42
Study 38374568 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactated Ringers (LR)
Number of subjects: 76
Study 38374568 — intervention group
Group type: COMPARATOR
Intervention: Normal Saline (NS)
Number of subjects: 76
Study 38375038 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam combined with low dose esketamine
Number of subjects: 0
Study 38375038 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol combined with low dose esketamine
Number of subjects: 0
Study 38375072 — intervention group
Group type: EXPERIMENTAL
Intervention: Avocado-supplemented diet (1 avocado per day)
Number of subjects: 1008
Study 38375072 — intervention group
Group type: EXPERIMENTAL
Intervention: Avocado-supplemented diet
Number of subjects: 1008
Study 38375072 — intervention group
Group type: COMPARATOR
Intervention: Habitual diet
Number of subjects: 1008
Study 38375411 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic gastric bypass (RGB)
Number of subjects: 153
Study 38375411 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic gastric bypass (LGB)
Number of subjects: 153
Study 38375429 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled APN01 (rhACE2)
Number of subjects: 0
Study 38375429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38375580 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention of Participation and Executive Functions (I-PEX) (n=13)
Number of subjects: 25
Study 38375580 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (n=12)
Number of subjects: 25
Study 38375637 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated donor-derived cell-free DNA (dd-cfDNA)
Number of subjects: 148
Study 38375637 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated cell-free mitochondrial DNA
Number of subjects: 148
Study 38375705 — intervention group
Group type: EXPERIMENTAL
Intervention: Frail group (n=42)
Number of subjects: 145
Study 38375705 — intervention group
Group type: COMPARATOR
Intervention: Nonfrail group (n=103)
Number of subjects: 145
Study 38375882 — intervention group
Group type: COMPARATOR
Intervention: Smartphone app
Number of subjects: 2703
Study 38375995 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide (8-12 mg/kg/day)
Number of subjects: 255
Study 38375995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study 38375995 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide
Number of subjects: 255
Study 38376015 — intervention group
Group type: EXPERIMENTAL
Intervention: Actigraphy device worn on the nondominant wrist for 21 days, recording CH attack-related data.
Number of subjects: 4
Study 38376181 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution spinal cord stimulation (HR-SCS)
Number of subjects: 18
Study 38376181 — intervention group
Group type: COMPARATOR
Intervention: Commercial paddle leads
Number of subjects: 18
Study 38376227 — intervention group
Group type: EXPERIMENTAL
Intervention: VIR-2482
Number of subjects: 100
Study 38376227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 38376229 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole intravenous (IV) and powder for oral suspension (PFS) formulations at dosing regimens of 3.5, 4.5, and 6 mg/kg
Number of subjects: 144
Study 38376229 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole 300 mg/day tablet in a virtual adolescent population (body weight >40 kg)
Number of subjects: 144
Study 38376229 — intervention group
Group type: COMPARATOR
Intervention: Posaconazole IV only
Number of subjects: 144
Study 38376518 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat food preference measured in fasted state
Number of subjects: 7
Study 38376518 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweet food reward measured as implicit wanting
Number of subjects: 7
Study 38376591 — intervention group
Group type: EXPERIMENTAL
Intervention: Seawater nasal wash (4-daily nasal washes with undiluted isotonic seawater)
Number of subjects: 355
Study 38376591 — intervention group
Group type: EXPERIMENTAL
Intervention: Seawater nasal wash
Number of subjects: 355
Study 38376593 — intervention group
Group type: EXPERIMENTAL
Intervention: Copenhagen Adduction Exercise (CAE)
Number of subjects: 30
Study 38376593 — intervention group
Group type: COMPARATOR
Intervention: Control group (rehabilitation program without CAE)
Number of subjects: 30
Study 38376596 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid gel (HyA)
Number of subjects: 56
Study 38376596 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 56
Study 38376596 — intervention group
Group type: COMPARATOR
Intervention: Presence of plaque
Number of subjects: 56
Study 38376596 — intervention group
Group type: COMPARATOR
Intervention: Time
Number of subjects: 56
Study 38376645 — intervention group
Group type: COMPARATOR
Intervention: Zonisamide 25 mg
Number of subjects: 69
Study 38376645 — intervention group
Group type: COMPARATOR
Intervention: Zonisamide 50 mg
Number of subjects: 69
Study 38376645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 38376643 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) + topical timolol-dorzolamide eye drops
Number of subjects: 46
Study 38376643 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal bevacizumab (IVB) alone (Control)
Number of subjects: 46
Study 38376651 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-week TDF (Arm A)
Number of subjects: 100
Study 38376651 — intervention group
Group type: COMPARATOR
Intervention: 48-week TDF (Arm B)
Number of subjects: 100
Study 38376858 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD diagnosis model using clinical, Shape, and Diameter characteristics
Number of subjects: 131
Study 38376858 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrahepatic involvement identification model using clinical, Shape, and Diameter characteristics
Number of subjects: 131
Study 38376926 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 40
Study 38376926 — intervention group
Group type: COMPARATOR
Intervention: Lonsurf (control)
Number of subjects: 40
Study 38376930 — intervention group
Group type: EXPERIMENTAL
Intervention: Compassion-based meditation intervention delivered via the Healthy Minds Program app
Number of subjects: 0
Study 38376930 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 38376992 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support interventions (specific details not provided)
Number of subjects: 0
Study 38377071 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant transarterial chemoembolization (PA-TACE)
Number of subjects: 1488
Study 38377071 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed HIPC scheme
Number of subjects: 1488
Study 38377166 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated directly observed therapy (DOT)
Number of subjects: 1655
Study 38377166 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated self-administered therapy (SAT)
Number of subjects: 1655
Study 38377166 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed choice between facilitated DOT and facilitated SAT
Number of subjects: 1655
Study 38377176 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab + Carboplatin/Etoposide Q3W for 4-6 cycles in the induction phase, followed by Atezolizumab maintenance Q3W
Number of subjects: 154
Study 38377234 — intervention group
Group type: EXPERIMENTAL
Intervention: Perivascular inflammation (assessed by pericoronary adipose tissue attenuation) in women
Number of subjects: 409
Study 38377234 — intervention group
Group type: COMPARATOR
Intervention: Perivascular inflammation (assessed by pericoronary adipose tissue attenuation) in men
Number of subjects: 409
Study 38377235 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaging-assessed stress-related neural activity
Number of subjects: 364
Study 38377256 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 0
Study 38377256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38377327 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified Meal Announcement
Number of subjects: 0
Study 38377327 — intervention group
Group type: COMPARATOR
Intervention: Precise Carbohydrate Counting
Number of subjects: 0
Study 38377520 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine; dosage and duration not available
Number of subjects: 0
Study 38377518 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 0
Study 38377526 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic testing
Number of subjects: 0